2024. Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s445. DOI:https://doi.org/10.25251/skin.8.supp.445.